Scancell a developer of novel immunotherapies for the treatment of cancer, is pleased to announce that a patent for its DNA ImmunoBody technology has now been granted in Europe
The European patent, number 2134357, granted by the European Patent Office, covers Scancell’s DNA ImmunoBody platform technology and is key to the protection of the Company’s pipeline of ImmunoBody vaccines, including lead candidates, SCIB1 and SCIB2.
On issuance, this patent will extend coverage of Scancell’s intellectual property into another important market for Scancell. Counterparts to this patent have already been granted in the US, Australia and Japan.
The European patent covers the following countries: Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, UK, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Sweden and Turkey.
Dr Richard Goodfellow, CEO of Scancell, said: “The addition of this key European patent for DNA ImmunoBody significantly bolsters our global intellectual property portfolio as we position the company for future growth.”